FRIDAY, Sept. 28 (HealthDay News) -- Wound healing in diabetic, obese mice can be significantly hastened by a systematic application of neutralizing monoclonal antibodies, which dramatically reduce the presence of inflammatory macrophages, according to a report in the September issue of the Journal of Investigative Dermatology.
Itamar Goren, of Johann Wolfgang Goethe University in Frankfurt, Germany, and colleagues assayed wound tissue from mice treated with monoclonal antibodies directed against tumor necrosis factor (TNF) alpha (V1q) and monocyte/macrophage-expressed EGF-like module-containing mucin-like hormone receptor-like (Emr)-1 (F4/80). Administration occurred by injection at days 7, 9 and 11 after injury, and was added to an ongoing systemic leptin treatment initiated two days before wounding.
The V1q and F4/80 treatments were associated with a "profound improvement" resulting in an observable "general resolution" in impaired wound tissue in the mice. A significant attenuation of inflammatory response at the wound site was also observed.
"In summary, our observations indicate a pivotal role for activated macrophages in the development of diabetes-impaired wound healing and strongly suggest a pharmacologic targeting of those activated macrophages as a promising therapeutic approach to improve impaired wound-healing conditions in general," the authors conclude.
Abstract
Full Text (subscription or payment may be required)
